Bod Science chief executive Jo Patterson said the results open the door for commercialisation. “This is a gold standard clinical trial which proves the efficacy of CBD and it’s so important for Bod and the rest of the industry,” she told Cannabiz. “We have spent a lot of money on research and now I believe we’re at the exciting tipping point of commercialisation. “I feel like we’ve done the heavy lifting for the last six years, and I’m super excited about taking that research into commercialisation and yielding the results of that hard work.” The news triggered a near-20% spike in Bod’s share price, which hit $0.08c at 1pm. Just how statistically different the results were will be known once the complete data set is released, in around five weeks’ time. Secondary and tertiary endpoints to assess CBD’s efficacy for anxiety and stress will also become clear when the full results are released.
Source: Cannabiz